Search results
Results from the WOW.Com Content Network
Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease....
We report 2 patients with CKD due to diabetic kidney disease who experienced rapid worsening of kidney function after being prescribed the GLP-1 receptor agonist semaglutide (Ozempic, Novo Nordisk, Inc., Bagsværd, Denmark).
This post-hoc analysis of individual patient data from the SUSTAIN 1–7 randomised controlled trials assessed the effects of the GLP-1 receptor agonist semaglutide on kidney function and safety across a large number and wide range of patients with type 2 diabetes.
The trial compared injectable semaglutide (1.0 mg) once weekly with a placebo as an adjunct to the standard of care for the prevention of major kidney outcomes, specifically kidney failure, substantial loss of kidney function, and death from kidney or cardiovascular causes.
We report 2 patients with CKD due to diabetic kidney disease who experienced rapid worsening of kidney function after being prescribed the GLP-1 receptor agonist semaglutide (Ozempic, Novo Nordisk, Inc., Bagsværd, Denmark).
Semaglutide, the compound in the blockbuster drugs Ozempic and Wegovy, dramatically reduced the risk of kidney complications, heart issues and death in people with Type 2 diabetes and chronic...
Background: Patients with type 2 diabetes have a high risk of developing chronic kidney disease. We examined the effects of semaglutide on kidney function and safety in a large, broad type 2 diabetes population.
On May 24, Ozempic manufacturer Novo Nordisk released the full results from its clinical trial, which shows that semaglutide, the active ingredient in this GLP-1 drug, can reduce the risk of...
Weekly injections of semaglutide medications like Ozempic significantly reduce the risk of serious kidney outcomes, major cardiovascular events and death among people who have type 2...
Researchers presented clinical-trial data today at a conference in Stockholm, showing that it significantly reduces the risk of kidney failure and death for people with type 2...